SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma reports Profit after tax of Rs 2773.50 Mln, in the December 2020 quarter

19 Jan 2021 Evaluate
The company witnessed a 17.43% growth in the revenue at Rs. 12357.70 millions for the quarter ended December 2020 as compared to Rs. 10523.60 millions during the year-ago period.A humble growth in net profit of 19.97% reported in the quarter ended December 2020 to Rs. 2773.50  millions from Rs. 2311.90 millions.The company reported a good operating profit of 3744.60 millions compared to 3214.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202012 201912 % Var 202012 201912 % Var 202003 201903 % Var
Sales 12357.70 10523.60 17.43 38942.10 30840.00 26.27 41325.50 36602.70 12.90
Other Income 27.00 2.90 831.03 57.00 37.50 52.00 1347.60 64.20 1999.07
PBIDT 3744.60 3214.10 16.51 12569.40 9103.70 38.07 13376.50 8850.90 51.13
Interest 22.10 69.30 -68.11 106.30 182.20 -41.66 251.80 148.70 69.33
PBDT 3722.50 3144.80 18.37 12463.10 8921.50 39.70 13024.70 8702.20 49.67
Depreciation 382.10 343.10 11.37 1107.60 993.20 11.52 1356.70 1055.90 28.49
PBT 3340.40 2801.70 19.23 11355.50 7928.30 43.23 11668.00 7646.30 52.60
TAX 566.90 489.80 15.74 1912.80 1377.40 38.87 1974.00 1534.20 28.67
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 2773.50 2311.90 19.97 9442.70 6550.90 44.14 9694.00 6112.10 58.60
Equity 393.10 377.00 4.27 393.10 377.00 4.27 377.00 377.00 0.00
PBIDTM(%) 30.30 30.54 -0.79 32.28 29.52 9.34 32.37 24.18 33.86

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×